Beam Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview

Beam Therapeutics

23/02/2024 14:10

* Beam Therapeutics Inc  BEAM.OQ   BEAM.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 6.8% decrease in revenue to $18.673 million from $20.04
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Beam Therapeutics Inc is
for a
loss of $1.01 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $41.50​, above​ its last closing price of $33.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.32       -1.36      -1.22     Beat    10.4
 Jun. 30 2023  -1.46       -1.42      -1.08     Beat    24.2
 Mar. 31 2023  -1.34       -1.34      -1.33     Beat    0.9​
 Dec. 31 2022  -1.40       -1.33      -0.54     Beat    59.3
 ​​Sep.        -1.31       -1.31      -1.56     Missed  -18.8
 30 2022                                                
 Jun. 30 2022  -1.10       -1.08      -1.02     Beat    5.4​
 Mar. 31 2022  -1.42       -1.32      -1.01     Beat    23.5
 Dec. 31 2021  -1.03       -1.03      -0.95     Beat    7.6
 This summary was machine generated February 23 at 14:10 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)